Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for political professionals · Friday, March 29, 2024 · 699,734,274 Articles · 3+ Million Readers

Antibody Discovery Services and Platforms Market, 2028

Dublin, Sept. 19, 2018 (GLOBE NEWSWIRE) -- The "Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028" report has been added to ResearchAndMarkets.com's offering.

The Antibody Discovery: Services and Platforms (2nd Edition), 2018-2028' report provides an extensive study on the current market landscape and future outlook of companies offering antibody discovery services and platforms.

Given the increasing focus on personalized medicine, biologics have established a strong foothold in the pharmaceutical industry. Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody based pharmacological interventions presently represent the largest class of biologics, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages.

It is worth mentioning that the research and development efforts associated with antibody-based therapeutics have significantly paced up in 2017; this momentum is projected to continue over the coming several years. In fact, in 2017, more than 10 monoclonal antibodies were approved by the FDA and EMA. Additionally, close to 20 monoclonal antibodies are currently being evaluated in late stages of clinical development. In addition to monoclonal antibodies, other novel antibody-based therapeutics, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, are steadily gaining traction.

The discovery of antibodies is a long, arduous and cost intensive process. As a result, many biopharmaceutical developers are opting to outsource such operations. Modern contract research organizations (CROs), offering antibody discovery services, claim to have novel and advanced technologies to support players developing antibody-based products in their early stage research requirements.

Additionally, there are a number of companies that have developed proprietary antibody discovery platforms and have made them available to drug developers. In-licensing the technology of such players for use in drug discovery operations is considered a viable business strategy, offering both time and cost related benefits to drug / therapy developers. As the demand for such therapeutic / diagnostic products increases, the opportunity for contract service provides and technology developers is also anticipated to grow in the foreseen future.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. We have provided insights on the likely evolution of the market in different regions, including North America, Europe, China and the rest of the world. In addition, we have provided the likely distribution of the opportunity across the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), and the nature of antibody generated (chimeric, humanized and fully human).


In addition, we have estimated the future opportunity for platform providers in term of the likely licensing deal structures and the agreements that are expected to be signed in the foreseen future.The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain.


The major share (over 80%) of revenues is anticipated to be distributed between North America and Europe; however, we believe that certain Asian countries, such as China, are likely to grow at faster rate (CAGR of 8.8%) as compared to other regions over the coming decade; this is attributed to the availability of skilled manpower, lower labor costs and a less stringent regulatory environment.
The sustained growth is also expected to result in lucrative monetizing opportunities for platform providers as they compete for a share within the USD 3 billion licensing deal revenues over the coming decade (in the form of upfront and milestone payments).


Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Antibody Discovery
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Bispecific Antibodies
3.6.3. Polyclonal Antibodies
3.7. Applications of Antibodies

4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In Vitro Display Methods
4.3.2.1. Phage Display Method
4.3.2.2. Yeast Display Method
4.3.2.3. Ribosomal Display Method
4.3.3. Transgenic Animals Based Method
4.3.4. Single B Cell Based Method
4.4. Advantages and Disadvantages of Antibody Discovery Methods
4.5. Evolution of Monoclonal Antibodies
4.5.1. Fully Human Monoclonal Antibodies

5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers: Overall Market Landscape
5.2.1. Analysis by Antibody Discovery Steps
5.2.2. Analysis by Antibody Discovery Methods
5.2.3. Analysis by Purpose of Antibody Discovery
5.2.4. Analysis by Type of Antibodies Discovered
5.2.5. Analysis by Animal Model Used
5.3. Antibody Discovery Platform Providers: Overall Market Landscape
5.3.1. Analysis by Antibody Discovery Methods
5.3.2. Analysis by Type of Antibodies Discovered
5.3.3. Analysis by Animal Model Used
5.3.4. Antibody Discovery Service and Platform Providers: Analysis by Geographical Location
5.4. Antibody Discovery Platform Providers: for In-house Purposes

6. BENCHMARK ANALYSIS
6.1. Chapter Overview
6.2. Benchmark Analysis: Methodology
6.3. Benchmark Analysis: Peer Groups
6.4. Benchmark Analysis: North America Based Companies
6.4.1. Peer Group I
6.4.2. Peer Group II
6.4.3. Peer Group III
6.5. Benchmark Analysis: Europe and Asia Pacific Based Companies
6.5.1. Peer Group IV
6.5.2. Peer Group V
6.5.3. Peer Group VI

7. COMPARATIVE ANALYSIS OF SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: Competitive Landscape
7.3. Antibody Discovery Service Providers: Comparative Analysis by Region
7.3.1. Key Players in North America
7.3.2. Key Players in Europe
7.3.3. Key Players in Asia Pacific

8. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
8.1. Chapter Overview
8.2. Antibody Discovery Service Providers in North America
8.2.1. Abwiz Bio
8.2.1.1. Company Overview
8.2.1.2. Financial Information
8.2.1.3. Antibody Discovery Services
8.2.1.4. Antibody Discovery Platforms
8.2.1.4.1. Needle-in-a-Haystack Technology
8.2.1.4.2. RabWiz
8.2.1.4.3. WizAmp
8.2.1.5. Recent Developments
8.2.1.5.1. Partnerships
8.2.1.6. Future Outlook
8.2.2. Aragen Bioscience (A GVK BIO Company)
8.2.2.1. Company Overview
8.2.2.2. Antibody Discovery Services
8.2.2.3. Recent Developments
8.2.2.3.1. Expansions
8.2.2.3.2. Partnerships
8.2.2.4. Future Outlook
8.2.3. Integral Molecular
8.2.3.1. Company Overview
8.2.3.2. Financial Information
8.2.3.3. Antibody Discovery Services
8.2.3.4. Recent Developments
8.2.3.5. Future Outlook
8.2.4. LakePharma
8.3. Antibody Discovery Service Providers in Europe
8.3.1. Abzena
8.3.2. MAB Discovery
8.3.3. ModiQuest Research (Acquired by ImmunoPrecise Antibodies)
8.3.3.1. Company Overview
8.3.3.2. Antibody Discovery Services
8.3.3.3. Antibody Discovery Platforms
8.3.3.3.1. ModiVacc
8.3.3.3.2. ModiFuse: Proprietary Hybridoma Platform
8.3.3.3.3. ModiSelect: Proprietary B Cell Selection Platform
8.3.3.3.4. ModiPhage: In-House and Custom Phage Libraries
8.3.3.3.5. ModiTune: Antibody Optimization Platform
8.3.3.3.6. ModiXpress: Proprietary In-House Expression Platform
8.3.4. PX'Therapeutics (Acquired by Aguettant Pharmaceutical Group)

8.4. Antibody Discovery Service Providers in Asia-Pacific
8.4.1. ChemPartner
8.4.2. Viva Biotech
8.4.3. WuXi AppTec

9. COMPETITIVENESS ANALYSIS OF ANTIBODY DISCOVERY PLATFORMS
9.1. Chapter Overview
9.2. Library Based Antibody Discovery Platforms
9.3. Transgenic Animal Based Antibody Discovery Platforms
9.4. Single Cell Based Antibody Discovery Platforms
9.5. Other Antibody Discovery Platforms

10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
10.1. Chapter Overview
10.2. Antibody Discovery Platform Providers in North America
10.2.1. Distributed Bio
10.2.1.1. Company Overview
10.2.1.2. Financial Information
10.2.1.3. Antibody Discovery Platforms
10.2.1.3.1. SuperHuman Platform
10.2.1.4. Recent Developments
10.2.1.5. Future Outlook
10.2.2. Invenra
10.2.3. Ligand Pharmaceuticals
10.2.3.3.1. OmniAb
10.2.4. Sorrento Pharmaceuticals
10.2.5. TRIANNI
10.2.6 Single Cell Technology
10.2.6.1. Company Overview
10.2.6.2. Financial Information
10.2.6.3. Antibody Discovery Platforms
10.2.6.4. Recent Developments
10.2.6.5. Future Outlook
10.3. Antibody Discovery Platform Providers in Europe
10.3.1. AIMM Therapeutics
10.3.2. BioInvent
10.3.3. Genmab
10.3.4. Kymab
10.4. Antibody Discovery Platform Providers in Asia-Pacific
10.4.1. Harbour BioMed

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Antibody Discovery Service and Platform Providers: List of Partnerships and Collaborations
11.3.1. Analysis by Number of Partnerships
11.3.2. Analysis by Type of Partnership
11.3.3. Most Active Players: Analysis by Number of Partnerships
11.4. Concluding Remarks

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. Antibody Discovery Services and Platforms Market: Funding and Investment Analysis
12.3.1. Analysis by Number of Funding Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Most Active Players
12.3.5. Analysis by Most Active Investors
12.4. Concluding Remarks

13. OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology
13.3. Antibody Discovery Services Market, 2018-2030 (USD Billion)
13.4. Antibody Discovery Services Market, 2018-2030: Distribution by Geography (USD Billion)
13.5. Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Steps (USD Billion)
13.6. Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods (USD Billion)
13.7. Antibody Discovery Services Market, 2018-2030: Distribution by Type of Antibody Generated (USD Billion)
13.8. Antibody Discovery Platforms Market, 2018-2030: Licensing Deals (USD Billion)
13.9. Antibody Discovery Platforms Market, 2018-2030: Upfront and Milestone Payments, 2018, 2025 and 2030

14. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
14.1. Chapter Overview
14.2. Humira (Adalimumab)
14.3. Rituxan (Rituximab)
14.4. Herceptin (Trastuzumab)
14.5. Remicade (Infliximab)
14.6. Avastin (Bevacizumab)

15. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION
15.1. Importance of Antibody Humanization and Affinity Maturation
15.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
15.3. Antibody Humanization: Publication Analysis
15.3.1. Publication Analysis: Year-Wise Trend
15.3.2. Publication Analysis: Key Journals
15.3.3. Publication Analysis: Distribution by Animal Model Used
15.3.4. Publication Analysis: Distribution by Method Used for Humanization
15.4. Antibody Humanization Service and Platform Providers: SWOT Analysis

16. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
16.1. Chapter Overview
16.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Formats
16.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
16.4. Transition to CADD-based Approaches
16.5. Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications
16.6. Growing Market Opportunities in the Asia-Pacific Region
16.7. Expected Increase in Number of Collaborations and Licensing Activity

17. SURVEY INSIGHTS
17.1. Chapter Overview
17.2. Designation of Respondents
17.3. Antibody Discovery Stages
17.4. Antibody Discovery Methods
17.5. Type of Antibody Discovered
17.6. Location of Antibody Discovery Facility / Laboratory
17.7. Likely Market Size

18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Aaron Sato, Chief Scientific Officer, LakePharma
18.3. Christel Iffland, Vice President, Ligand Pharmaceuticals
18.4. Chun-Nan Chen, Chief Executive Officer & Chief Scientific Officer, Single Cell Technology
18.5. Debra Valsamis, Business Development Associate, Antibody Solutions
18.6. Garren Hilow, Co-Founder and Chief Executive Officer, Abveris
18.7. Giles Day, Co-Founder and Chief Executive Officer, Distributed Bio
18.8. Ignacio Pino, President and Chief Executive Officer, CDI Laboratories
18.9. Jeng Her, Chief Executive Officer, AP Biosciences
18.10. Kevin Heyries, Co-Founder and Lead of Business Development Strategy, AbCellera
18.11. Nalini Ghag- Motwani, President and Founding Chief Scientist, BioSavita
18.12. Sanjiban K Banerjee, Director, AbGenics Life Sciences
18.13. Thomas Schirrmann, Chief Executive Officer and General Manager, YUMAB

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

  • 4-Antibody
  • A*STAR's Genome Institute of Singapore
  • AB Biosciences
  • Ab Studio
  • ABBA Therapeutics
  • AbBioSci
  • AbbVie
  • AbCellera
  • AbCheck
  • Abeome
  • AbGenics Life Sciences
  • Abgent
  • Ablexis
  • Abpro
  • Absolute Antibody
  • Abwiz Bio
  • Abzena
  • Abzyme Therapeutics
  • Accel
  • Acceleron Pharma
  • Accurus Biosciences
  • Achaogen
  • ACROBiosystems
  • ACYTE Biotech
  • Adagene
  • Adimab
  • Aduro Biotech
  • Advantech Capital
  • Agenus
  • AIMM Therapeutics
  • Aitua
  • Akeagen
  • Alder BioPharmaceuticals
  • Alector
  • Alere
  • Alexandria Real Estate Equities
  • Alexion Pharmaceuticals
  • Ally Bridge Group
  • Amdec Group
  • Amgen
  • Ampersand Capital Partners
  • AnaptysBio
  • AP Biosciences
  • Apexigen
  • Aquila Capital
  • Aragen Bioscience
  • ARCH Venture Partners
  • Argenx
  • Aridis Pharmaceuticals
  • Aristi Biotech
  • Astellas Venture Management
  • AstraZeneca
  • Atlas Venture
  • Atreca
  • AvantGen
  • Avlar BioVentures
  • AxioMx
  • Ballast Point Ventures
  • Bayer
  • BASF
  • BBI Group
  • BeiGene
  • Beijing Shijilongxin Investment
  • Berkeley Lights
  • Bill & Melinda Gates Foundation
  • BioAtla
  • Biogen
  • BioGeneration Ventures
  • BioInvent International
  • BioLauncher
  • Biomirex
  • BioNTech
  • Bio-Rad
  • BioRap Technologies
  • Biosin
  • BIOTEM
  • Birchmere Labs
  • Bird Rock Bio
  • Blue Sky BioServices
  • bluebird bio
  • Boehringer Ingelheim
  • Borealis Ventures
  • Bristol-Myers Squibb
  • Brigham and Women's Hospital
  • Burrage Capital
  • BVF Partners
  • Canaan Partners
  • Cambridge Antibody Technology
  • Capra Science Antibodies
  • Case Western Reserve University School of Medicine
  • Catalent Biologics
  • Celexion
  • Celgene
  • Cellectis
  • Celltrion
  • Centers for Disease Control and Prevention
  • ChemBio Discovery Solutions
  • ChemPartner
  • Chiome Bioscience
  • Chugai Pharmaceutical
  • Chugai Pharmabody Research
  • Cisbio
  • CNA Development
  • Compass Therapeutics
  • Compugen
  • Commission for Technology and Innovation
  • ContraFect
  • Corixa
  • Cormorant Pharmaceuticals
  • Cosmo Pharmaceuticals
  • Creative Biolabs
  • Crescendo Biologics
  • Cresset Biomolecular Discovery
  • Crucell
  • Crystal Bioscience
  • Cullinan Oncology
  • Cytogen
  • DAFNA Capital Management
  • Daiichi Sankyo
  • Dako
  • Dana-Farber Cancer Institute
  • DaTaMabs
  • Defense Threat Reduction Agency
  • Department of Health and Human Services
  • Digital Proteomics
  • Distributed Bio
  • DJS Antibodies
  • Dyax
  • Effimune
  • Elan
  • Eli Lilly
  • Elusys Therapeutics
  • EMBL Ventures
  • Emergent BioSolutions
  • Emory University
  • Enthera
  • Enumeral
  • EpiCypher
  • EpimAb Biotherapeutics
  • Erasmus MC Biomedical Fund
  • Essex Bio-Technology
  • Eureka Therapeutics
  • European Investment Bank
  • EVA Basel
  • Evotec
  • Exiris
  • FairJourney Biologics
  • Ferring Pharmaceuticals
  • Five Prime Therapeutics
  • Flanders Innovation and Entrepreneurship
  • Floodgate Fund
  • Forbion Capital Partners
  • Fred Hutchinson Cancer Research Center
  • Fresenius
  • F-star
  • Fusion Antibodies
  • G&P Biosciences
  • Genedata
  • GeneBeyond
  • GeneFrontier
  • Genentech
  • Genetix
  • Genmab
  • Genor Biopharma
  • GenScript
  • Genzyme
  • Georgia Institute of Technology
  • GigaGen
  • Gilead Sciences
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • GlycoNex
  • Grenoble Hospital
  • GTJA Investment Group
  • GVK Biosciences
  • Harbour BioMed
  • Harpoon Therapeutics
  • HD Biosciences
  • HealthCare Ventures
  • Henlix Biotech
  • Heptares Therapeutics
  • Hercules Capital
  • HitGen
  • HQL Pharmaceuticals
  • Humabs BioMed
  • Human Genome Sciences
  • IBC Generium
  • Ibex Biosciences
  • IGEM Therapeutics
  • Igenica Biotherapeutics
  • ImClone Systems
  • Immune Biosolutions
  • Immunex
  • ImmunoChina Pharmaceuticals
  • Immunologix
  • Immunome
  • Immunomedics
  • Immunomic Therapeutics
  • ImmunoPrecise Antibodies
  • Imperial Innovations
  • In-Cell-Art
  • Innovate UK
  • Innovative Targeting Solutions
  • Innovent Biologics
  • Institut Pasteur
  • Institute for the Promotion of Innovation by Science and Technology
  • Integral Molecular
  • Intrexon
  • Invenra
  • IONTAS
  • Isogenica
  • iTeos Therapeutics
  • Janssen Biotech
  • Jazz Pharmaceuticals
  • Jiangsu Hengrui Medicine
  • Johnson & Johnson
  • Jounce Therapeutics
  • Juno Therapeutics
  • Kaken Pharmaceutical
  • KBC Private Equity
  • KindredBio
  • King Star
  • Kite Pharma
  • Kodiak Sciences
  • Kymab
  • Kyowa Hakko Kirin
  • LakePharma
  • Leland Stanford Junior University
  • LEO Pharma
  • Les Laboratoires Servier
  • Life Sciences Partners
  • Ligand Pharmaceuticals
  • Lilly Asia Ventures
  • LYFE Capital
  • MAB Discovery
  • MabPlex
  • MabSpace Biosciences
  • MabVax Therapeutics
  • MacroGenics
  • Magenta Therapeutics
  • Malin
  • Massachusetts General Hospital
  • MassBiologics
  • Maverick Therapeutics
  • MD Anderson Cancer Center
  • Medarex
  • Medical Research Council
  • MediMabs
  • MedImmune
  • Meditope Biosciences
  • MEMO Therapeutics
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Mersana Therapeutics
  • Merus
  • MidCap Financial
  • Millennium Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • ModiQuest Research
  • Molcure
  • Molecular Devices
  • Molecular Templates
  • Moradec
  • MorphoSys
  • MPM Capital
  • MSM Protein Technologies
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • NB Health Laboratory
  • NBE Therapeutics
  • NeoClone
  • Nst.Bio Ventures
  • Neurimmune
  • NGM Biopharmaceuticals
  • North Coast Biologics
  • NovaRock Biotherapeutics
  • Novartis
  • Novimmune
  • Novo Nordisk
  • Numab
  • NXT Ventures
  • Oak BioSciences
  • Olympic Protein Technologies
  • Omnes Capital
  • OncoMed Pharmaceuticals
  • Oncobiologics
  • Oncothyreon
  • Ono Pharmaceutical
  • Open Monoclonal Technology
  • OrbiMed Advisors
  • Organon Teknika
  • ORI Healthcare Fund
  • OriMAbs
  • Ossianix
  • Oxford BioTherapeutics
  • Ozyme
  • Palatin Technologies
  • Pfizer
  • PharmAthene
  • Phylogica
  • Pierre Fabre
  • Polaris Partners
  • Porton Pharma Solutions
  • Potenza Therapeutics
  • Prime Value Capital Management
  • ProteoGenix
  • Proxima Ventures
  • Pure Biologics
  • PX'Therapeutics
  • Qianhai Fund of Funds
  • Qiming Venture Partners
  • QoolAbs
  • Quanta BioDesign
  • Queen Mary University of London
  • RayBiotech
  • Redalpine Venture Partners
  • Regeneron Pharmaceuticals
  • Research Corporation Technologies
  • ResearchPoint Global
  • ribOvax Biotechnologies
  • Roche
  • Rx Biosciences
  • SAB Biotherapeutics
  • Sanofi
  • Scripps Research Institute
  • Sea Lane Biotechnologies
  • Seattle Genetics
  • Selexis
  • Sequoia Capital
  • Sevion Therapeutics
  • Shanghai Jianxin Capital
  • ShangPharma Innovation
  • Shenogen Pharma
  • Shenzhen Capital Group
  • Shenzhen Hepalink Pharmaceutical
  • Shenzhen Innovation Investment Group
  • Shenzhen Xinnuo Health Industry Investment
  • Shire
  • Siamab Therapeutics
  • Silicon Valley Bank
  • Silverton Partners
  • Singapore Immunology Network
  • Single Cell Technology
  • Sino Biological
  • Soligenix
  • Sorrento Therapeutics
  • SOTIO
  • Specifica
  • Spectrum Pharmaceuticals
  • Sphere Fluidics
  • Stanford University
  • Sucampo Pharmaceuticals
  • Surface Oncology
  • Sutro Biopharma
  • SV Life Sciences
  • Swedish Orphan Biovitrum
  • Symphogen
  • Synthetic Biologics
  • Synthon Biopharmaceuticals
  • Takeda Pharmaceutical
  • Tanabe Research Laboratories
  • TeneoBio
  • TetraGenetics
  • Teva Pharmaceutical
  • The French National Institute of Health and Medical Research
  • Theraclone Sciences
  • Theranyx
  • Tizona Therapeutics
  • Torch Biosciences
  • Transgene
  • TransGenic
  • Trellis Bioscience
  • TRIANNI
  • Tri-Institutional Therapeutics Discovery Institute
  • TriWise Capital
  • Twist Bioscience
  • U3 Pharma
  • UCB
  • United Therapeutics
  • University of California
  • University of Southampton
  • University of Texas
  • University of Turku
  • Vaccinex
  • Valeant Pharmaceuticals
  • venBio
  • Versant Ventures
  • VI Ventures
  • Viva Biotech
  • Viventia Bio
  • Wellcome Trust Sanger Institute
  • Woodford Investment Management
  • WuXi AppTec
  • Wyeth
  • XBiotech
  • xCella Biosciences
  • XOMA
  • YUMAB
  • YuRoGen Biosystems
  • Zebra Biologics
  • ZENOAQ
  • Zurich Cantonal Bank
  • Zymeworks

For more information about this report visit https://www.researchandmarkets.com/research/r2rn23/antibody?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Biopharmaceuticals 
                    

22157.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release